NUCALA should not be administered to patients with a history of hypersensitivity to mepolizumab or excipients in the formulation.


Blood eosinophils reduced within 4 weeks of treatment

Following subcutaneous (SC) administration of NUCALA every 4 weeks for 32 weeks in Trial 2, blood eosinophils were reduced by 84% compared with placebo. This magnitude of reduction was observed within 4 weeks of treatment and was maintained throughout the treatment period.  

The clinical significance of these data is unknown.

   818428R0 April 2017